[Antitumor activity of lycorine in renal cell carcinoma ACHN cell line and its mechanism].
OBJECTIVE
To investigate the antitumor effect of lycorine on renal cell carcinoma ACHN cells and explore the possible mechanism.


METHODS
We used flow cytometry to examine the effect of lycorine on ACHN cell cycle and apoptosis. The cell proliferation, migration and invasion were assessed with MTS assay, wound healing assay, and Transwell assay, respectively. Colony forming assay was performed, and the mRNA and protein levels of Bax, Bcl-2, survivin, caspase-3, cyclin D1 and CDK4 were measured with qRT-PCR and Western blotting.


RESULTS
Lycorine obviously inhibited the proliferation of ACHN cells with an IC(50) of 24.34 µmol/L. Lycorine also induced apoptosis of ACHN cells, caused cell cycle arrest at G(0)/G(1) phase, and suppressed the colony forming ability of the cells in a dose-dependent manner. The migration and invasion of ACHN cells were significantly inhibited by 5 µmol/L lycorine. Lycorine up-regulated the mRNA levels of CDK4, Bax, caspase-3 while down-regulated the levels of survivin, Bcl-2 and Cyclin D1; the protein levels of CDK4 and Bax were increased and cyclin D1, Bcl-2 and surviving expressions were decreased, but caspase-3 expression showed no significant changes following the treatment.


CONCLUSIONS
Lycorine has obvious antitumor effect against ACHN cells, suggesting its value as a new therapeutic agent for renal cell carcinoma.
Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. E-mail: 402953667@qq.com.
Yi-Qiang
YQ
Huang
Yi-Ming
YM
Zhang
Zhong
Z
Jin
Xie-Zhao
XZ
Li
Chong-Shan
CS
Wang
Kai
K
Xu
Peng
P
Huang
Chun-Xiao
CX
Liu
D047151:Amaryllidaceae Alkaloids / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D053148:Caspase 3 / Q000378:metabolism; D059447:Cell Cycle Checkpoints; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation; D019938:Cyclin D1 / Q000378:metabolism; D051358:Cyclin-Dependent Kinase 4 / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D010617:Phenanthridines / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D000077022:Survivin; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D047151:Amaryllidaceae Alkaloids; D000972:Antineoplastic Agents, Phytogenic; C494826:BAX protein, human; C000595707:BCL2 protein, human; C107489:BIRC5 protein, human; C530104:CCND1 protein, human; D051034:Inhibitor of Apoptosis Proteins; D010617:Phenanthridines; D019253:Proto-Oncogene Proteins c-bcl-2; D000077022:Survivin; D051028:bcl-2-Associated X Protein; D019938:Cyclin D1; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4; C505407:CASP3 protein, human; D053148:Caspase 3; C015330:lycorine